U.S. flag

An official website of the United States government

NM_024301.5(FKRP):c.1387A>G (p.Asn463Asp) AND Cardiovascular phenotype

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Feb 23, 2024
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV004018553.1

Allele description [Variation Report for NM_024301.5(FKRP):c.1387A>G (p.Asn463Asp)]

NM_024301.5(FKRP):c.1387A>G (p.Asn463Asp)

Gene:
FKRP:fukutin related protein [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
19q13.32
Genomic location:
Preferred name:
NM_024301.5(FKRP):c.1387A>G (p.Asn463Asp)
HGVS:
  • NC_000019.10:g.46756837A>G
  • NG_008898.2:g.15792A>G
  • NM_001039885.3:c.1387A>G
  • NM_024301.5:c.1387A>GMANE SELECT
  • NP_001034974.1:p.Asn463Asp
  • NP_077277.1:p.Asn463Asp
  • NP_077277.1:p.Asn463Asp
  • LRG_761t1:c.1387A>G
  • LRG_761:g.15792A>G
  • LRG_761p1:p.Asn463Asp
  • NC_000019.9:g.47260094A>G
  • NM_024301.4:c.1387A>G
  • NM_024301.5(FKRP):c.1387A>GMANE SELECT
  • Q9H9S5:p.Asn463Asp
Protein change:
N463D; ASN463ASP
Links:
UniProtKB: Q9H9S5#VAR_065063; OMIM: 606596.0018; dbSNP: rs121908110
NCBI 1000 Genomes Browser:
rs121908110
Molecular consequence:
  • NM_001039885.3:c.1387A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_024301.5:c.1387A>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Cardiovascular phenotype
Identifiers:
MedGen: CN230736

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV005028113Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Pathogenic
(Feb 23, 2024)
germlineclinical testing

PubMed (3)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

A novel FKRP mutation in congenital muscular dystrophy disrupts the dystrophin glycoprotein complex.

MacLeod H, Pytel P, Wollmann R, Chelmicka-Schorr E, Silver K, Anderson RB, Waggoner D, McNally EM.

Neuromuscul Disord. 2007 Apr;17(4):285-9. Epub 2007 Mar 1.

PubMed [citation]
PMID:
17336067

Molecular Analysis Confirms that FKRP-Related Disorders are Underdiagnosed in Mexican Patients with Neuromuscular Diseases.

Navarro-Cobos MJ, González-Del Angel A, Estandia-Ortega B, Ruiz-Herrera A, Becerra A, Vargas-Ramírez G, Bermúdez-López C, Alcántara-Ortigoza MA.

Neuropediatrics. 2017 Dec;48(6):442-450. doi: 10.1055/s-0037-1607054. Epub 2017 Oct 24. No abstract available.

PubMed [citation]
PMID:
29065428
See all PubMed Citations (3)

Details of each submission

From Ambry Genetics, SCV005028113.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (3)

Description

The p.N463D pathogenic mutation (also known as c.1387A>G), located in coding exon 1 of the FKRP gene, results from an A to G substitution at nucleotide position 1387. The asparagine at codon 463 is replaced by aspartic acid, an amino acid with highly similar properties. This alteration has been reported in the homozygous state in multiple individuals with congenital muscular dystrophy, including hypotonia, motor delay, and elevated CK (MacLeod H et al. Neuromuscul. Disord., 2007 Apr;17:285-9; Navarro-Cobos MJ et al. Neuropediatrics, 2017 12;48:442-450; Lee AJ et al. Neurol Genet, 2019 Apr;5:e315). In addition, this variant has been reported in trans with a second FKRP alteration (Navarro-Cobos MJ et al. Neuropediatrics, 2017 12;48:442-450; Lee AJ et al. Neurol Genet, 2019 Apr;5:e315). It has been suggested that this might be a founder allele in individuals with Latino ancestry (Navarro-Cobos MJ et al. Neuropediatrics, 2017 12;48:442-450). Muscle biopsy from individuals homozygous for this alteration showed myopathic changes including variation in myofiber size, fatty replacement and endomysial fibrosis, absent alpha-dystroglycan staining, reduction in beta-dystroglycan as well as alpha-, beta-, and gamma-sarcoglycan staining, and mild focal reduction of dystrophin and merosin staining (MacLeod H et al. Neuromuscul. Disord., 2007 Apr;17:285-9). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 10, 2024